On 3 September, Dynacure released a letter to our patient community to include questions such as:-

What are the goals of the Phase 1/2 clinical trial?

When will the study start and where will it be run?

Why is Dynacure starting their trials in adults?

They also give a comprehensive explanation of how ASO technology works, and how a therapy gets to patients and what the next phase of this trial is likely to be.

To read more, please click on the PDF below or see the full press release, on Dynacure’s own website, here.

Dynacure Letter to Patient Community in English – 3 September 2019

Dynacure Letter to Patient Community in Italian – 3 September 2019

Dynacure Letter to Patient Community in Dutch – 3 September 2019

Dynacure Letter to Patient Community in Polish – 3 September 2019

Dynacure Letter to Patient Community in German – 3 September 2019

Dynacure Letter to Patient Community in Spanish – 3 September 2019

Dynacure Letter to Patient Community in Danish – 3 September 2019